GSK and Bharat Biotech to Halve Malaria Vaccine Price, Aiming for Under $5 per Dose by 2028

In the "epic battle" against malaria, GSK and India's Bharat Biotech are undoubtedly the "dream team." As long-time partners, these two companies have recently gone all out to deliver the world’s first malaria vaccine at a "rock-bottom price" to more countries in desperate need. This move is nothing short of a "price assassin eliminator" in the pharmaceutical world!

Mosquirix Debuts: The "Game-Changer" in the Vaccine World Emerges

Let's turn back the clock to 2021, when GSK, in collaboration with PATH (formerly known as the Program for Appropriate Technology in Health), grandly launched the malaria vaccine Mosquirix (also known as RTS.S) onto the global stage. This is no ordinary vaccine; it is the first malaria vaccine to receive the official recommendation and certification from the World Health Organization (WHO). It debuted directly in the spotlight, becoming the "top star" in the vaccine world and immediately capturing global attention.

Bharat "Quick Join": The "Rapid Force" in Vaccine Production

As a "senior supplier" of the Global Alliance for Vaccines and Immunization (Gavi), Bharat Biotech’s speed could rival “The Flash.” Upon hearing about a cooperation opportunity, the company swiftly signed an agreement to join the “large force” of antigen production, ready to “make a big move” with GSK. The purpose of this operation is clear: to expand the long-term vaccine supply and help GSK achieve its ambitious goal of providing up to 15 million doses of vaccines by 2028. Moreover, Bharat Biotech isn’t just all talk— it has invested over $200 million into building high-capacity production facilities and various upgrade projects, truly showcasing its “money-powered” capabilities.

The measure to gradually reduce the price to less than $5 per dose will fully take effect in 2028, by which time GSK and Bharat Biotech will have completed their production transfer.

Price "Plummeting": A "Fire Sale" in the Vaccine Industry?

On June 25, the two companies issued a press release, revealing a bombshell: thanks to GSK's "huge investment" in capacity and efficiency, vaccine prices are about to enter a "plummeting mode"! This is no small change—prices will gradually drop by over 50%. By 2028, the price per dose is set to fall below $5. At this price, it’s even cheaper than a cup of milk tea—a true “fire sale” in the vaccine world—all to make life-saving vaccines more accessible to people.

Big Shot's Speech: The "Passionate Declaration" Behind the Cooperation

Thomas Breuer, Chief Global Health Officer of GSK, passionately stated in the announcement: "We 'teamed up' with Bharat Biotech back in 2021 with only one goal: to find a sustainable way to defeat malaria. The results announced today are a key milestone achieved through the joint efforts of our team, including Bharat, Gavi, PATH, and the WHO." His words were filled with the热血 (passion) and豪情 (determination) shared among "comrades-in-arms."

Gavi's "Five-Year Plan": The "Grand Blueprint" for the Vaccine Industry

This commitment is actually part of the "Big Plan" for Gavi, the International Vaccine Alliance's upcoming replenishment phase from 2026 to 2030. Gavi 6.0, this five-year strategic framework, is considered the "grand blueprint" in the vaccine world. Its goal is to expand global vaccine accessibility, strengthen health systems, and ensure that immunization programs and vaccine markets are stable and sustainable through long-term, reliable funding.

Africa's "Immunization Program": Many Hands Make Light Work

GSK's statement also mentioned that by the end of 2025, Gavi aims to introduce Mosquirix into the routine immunization programs of 12 malaria-endemic countries in Africa. This is no easy task and achieving this goal relies on the collective efforts of GSK, Bharat Biotech, PATH, WHO, and other global health organizations working together. Dr. Seth Berkley, CEO of Gavi, also stated that the latest agreement between GSK and Bharat Biotech represents a significant step towards Gavi’s goal of providing malaria protection to at least 50 million children in Africa by the end of 2030 — "Promising!"

Assistance in "Changing Winds and Clouds": The "Perilous Challenges" of Malaria Prevention and Treatment

However, the road to combating malaria has not been smooth sailing. Data from the World Health Organization shows that nearly half of the global population faces the risk of malaria. Although investments in global malaria response since 2000 have prevented over 13 million deaths and at least 2 billion cases, recent cuts in foreign aid funding have posed significant challenges to malaria prevention programs. Take the United States, for example: in the 2026 budget proposal, funding for the U.S. President’s Malaria Initiative (PMI) was slashed by 47%, reducing the annual allocation to $424 million — a painful cut indeed!

Gates’ “Timely Help”: A “Much-Needed Rain” in the Charity World

At a critical moment, billionaire philanthropist Bill Gates stepped forward with a warning: "Due to significant cuts in foreign aid, the number of global child deaths this year may rise for the first time in decades—a tragedy by all means." Meanwhile, the Gates Foundation didn’t hesitate either. On Tuesday, it announced a pledge of $1.6 billion to Gavi over the next five years ahead of a donor conference co-hosted with the EU. This move has been likened to 'timely rain' in the charity world, giving a major boost to Gavi’s fundraising efforts, which aim to secure at least $9 billion.

"Next-Generation Vaccines Poised for Breakthrough: The 'Rising Stars' of the Vaccine Industry"

As price wars and funding battles rage on in China, GSK hasn't been sitting idle either — it has already begun developing the next generation of malaria vaccines. This vaccine will incorporate a new antigen that targets the malaria parasite at different stages of its life cycle, making it a "rising star" in the vaccine field. Katie Ewer, head of GSK's second-generation malaria vaccine project, revealed that in addition to enhancing disease protection, the second-generation vaccine may also reduce the number of booster shots required, making it more convenient and easier to promote within routine immunization programs — truly a game-changing upgrade!